CY1123527T1 - Αντιφυματικος παραγοντας - Google Patents

Αντιφυματικος παραγοντας

Info

Publication number
CY1123527T1
CY1123527T1 CY20201101104T CY201101104T CY1123527T1 CY 1123527 T1 CY1123527 T1 CY 1123527T1 CY 20201101104 T CY20201101104 T CY 20201101104T CY 201101104 T CY201101104 T CY 201101104T CY 1123527 T1 CY1123527 T1 CY 1123527T1
Authority
CY
Cyprus
Prior art keywords
dimethylphenoxy
pyrimidin
piperidin
dione
methyl
Prior art date
Application number
CY20201101104T
Other languages
English (en)
Inventor
Lluis Ballell Pages
David Barros-Aguirre
Robert H BATES
Julia Castro Pichel
Jorge ESQUIVIAS PROVENCIO
Kevin Pethe
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of CY1123527T1 publication Critical patent/CY1123527T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στη χρήση της 6-((4-(2,3-διμεθυλφαινοξυ)πιπεριδιν-1-υλ)μεθυλ)πυριμιδιν-2,4(1Η,3Η)-διόνης ή ενός φαρμακευτικά αποδεκτού άλατος αυτής στη θεραπεία, που περιλαμβάνει τη χρήση ως αντιμυκοβακτηριδιακού, για παράδειγμα στην αγωγή της φυματίωσης• σε συνθέσεις περιέχουσες 6-((4-(2,3-διμεθυλφαινοξυ)πιπεριδιν-1-υλ)μεθυλ)πυριμιδιν-2,4(1Η,3Η)-διόνη• σε συνδυασμούς που περιλαμβάνουν 6-((4-(2,3-διμεθυλφαινοξυ)πιπεριδιν-1-υλ)μεθυλ)πυριμιδιν-2,4(1Η,3Η)-διόνη ή ένα φαρμακευτικά αποδεκτό άλας αυτής και άλατα της 6-((4-(2,3-διμεθυλφαινοξυ)πιπεριδιν-1-υλ)μεθυλ)πυριμιδιν-2,4(1Η,3Η)-διόνης.
CY20201101104T 2016-03-22 2020-11-20 Αντιφυματικος παραγοντας CY1123527T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382124 2016-03-22
PCT/EP2017/056565 WO2017162591A1 (en) 2016-03-22 2017-03-20 Antituberculosis agent

Publications (1)

Publication Number Publication Date
CY1123527T1 true CY1123527T1 (el) 2022-03-24

Family

ID=55752236

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101104T CY1123527T1 (el) 2016-03-22 2020-11-20 Αντιφυματικος παραγοντας

Country Status (23)

Country Link
US (1) US10624893B2 (el)
EP (1) EP3432887B1 (el)
JP (1) JP6961608B2 (el)
KR (1) KR102479358B1 (el)
CN (1) CN108883114B (el)
AR (1) AR107935A1 (el)
AU (1) AU2017237380B2 (el)
CA (1) CA3018611C (el)
CY (1) CY1123527T1 (el)
DK (1) DK3432887T3 (el)
ES (1) ES2833929T3 (el)
HR (1) HRP20201861T1 (el)
HU (1) HUE051349T2 (el)
LT (1) LT3432887T (el)
PL (1) PL3432887T3 (el)
PT (1) PT3432887T (el)
RS (1) RS61103B1 (el)
RU (1) RU2756208C2 (el)
SI (1) SI3432887T1 (el)
TW (1) TW201808295A (el)
UY (1) UY37161A (el)
WO (1) WO2017162591A1 (el)
ZA (1) ZA201806012B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110004074B (zh) * 2019-02-28 2021-06-18 北京蛋白质组研究中心 一种利用silac标记耻垢分枝杆菌蛋白质的方法及其专用培养基
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CN115902217B (zh) * 2023-03-08 2023-06-16 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 一种牛副结核病间接elisa检测试剂盒及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2188196C2 (ru) * 1998-05-26 2002-08-27 Ашкинази Римма Ильинична N-замещенные производные 5-оксииминобарбитуровой кислоты
AU2964899A (en) * 1998-12-04 2000-06-26 Rimma Iliinichna Ashkinazi 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
EP1655288A1 (en) * 2004-11-05 2006-05-10 Institut Pasteur Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents

Also Published As

Publication number Publication date
PL3432887T3 (pl) 2021-05-17
RS61103B1 (sr) 2020-12-31
UY37161A (es) 2017-09-29
AU2017237380B2 (en) 2019-12-19
KR20180122006A (ko) 2018-11-09
AU2017237380A1 (en) 2018-09-27
JP2019512524A (ja) 2019-05-16
AR107935A1 (es) 2018-06-28
RU2018136747A (ru) 2020-04-22
DK3432887T3 (da) 2020-11-09
SI3432887T1 (sl) 2020-12-31
EP3432887B1 (en) 2020-09-02
JP6961608B2 (ja) 2021-11-05
RU2018136747A3 (el) 2020-05-15
PT3432887T (pt) 2020-12-04
LT3432887T (lt) 2020-12-10
US20190091224A1 (en) 2019-03-28
CN108883114B (zh) 2021-08-24
HUE051349T2 (hu) 2021-03-01
EP3432887A1 (en) 2019-01-30
ES2833929T3 (es) 2021-06-16
RU2756208C2 (ru) 2021-09-28
US10624893B2 (en) 2020-04-21
WO2017162591A1 (en) 2017-09-28
HRP20201861T1 (hr) 2021-01-08
BR112018069487A2 (pt) 2019-02-12
KR102479358B1 (ko) 2022-12-19
CA3018611A1 (en) 2017-09-28
CN108883114A (zh) 2018-11-23
ZA201806012B (en) 2020-02-26
TW201808295A (zh) 2018-03-16
CA3018611C (en) 2024-02-27

Similar Documents

Publication Publication Date Title
CY1123527T1 (el) Αντιφυματικος παραγοντας
CY1125613T1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1120941T1 (el) Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
CL2018002924A1 (es) Inhibidores de bromodominios
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
CY1122170T1 (el) Ορβεπιταντη για τη θεραπευτικη αγωγη χρονιου βηχα
CY1121334T1 (el) Αναστολεας κινασης aurora a